AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
The stock's fall snapped a two-day winning streak.
5h
RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
Hosted on MSN2d
Is AbbVie Stock Underperforming the Dow?North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.
AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback